Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jessicca Rege"'
Autor:
Lucy Gilbert, Jameel Muzaffar, David McDermott, Vamsidhar Velcheti, Anna Spreafico, Valentina Boni, Christopher Hoimes, Ira Winer, Seth Rosen, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Debora Bruno, Elizabeth Dorn, Jessicca Rege
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/5558dc32bb3f46a4a9c1044cc2c6eec4
Autor:
Thomas Herzog, John Hays, Kathleen Moore, Panagiotis Konstantinopoulos, Lucy Gilbert, Bradley Monk, David O’Malley, Joyce Barlin, Jessicca Rege, Monali Desai, Yangchun Du, Rita Dalal, Robert L Coleman, Jalid Sehouli
Publikováno v:
E-Posters (Trials In Progress).
Publikováno v:
Journal of Clinical Oncology. 38:e16537-e16537
e16537 Background: Bavituximab, an investigational, chimeric monoclonal antibody designed to inhibit the immunosuppressive effects of phosphatidylserine (PS), is being evaluated in combination with pembrolizumab in patients with advanced gastric and
Autor:
Ian Chau, Johanna C. Bendell, Kerry Culm-Merdek, Jeeyun Lee, Jessicca Rege, Andrew William Pippas
Publikováno v:
Journal of Clinical Oncology. 38:TPS459-TPS459
TPS459 Background: The majority of gastric cancer (GC) patients fail to derive sufficient benefit from currently available therapies. Pembrolizumab received accelerated approval in 2017 as a third-line therapy in PD-L1 positive GC patients with an OR
Autor:
Hendrik-Tobias Arkenau, Jin Jin, Ian Chau, Johanna C. Bendell, Gu Mi, Roy S. Herbst, Jessicca Rege, David Ferry
Publikováno v:
Annals of Oncology. 28:iii144-iii145
Autor:
Gu Mi, Johanna C. Bendell, Juan Martin-Liberal, Luis Paz-Ares, Emiliano Calvo, Jin Jin, Nicolas Isambert, Jessicca Rege, Philippe A. Cassier, Roy S. Herbst
Publikováno v:
Annals of Oncology. 28:ii32-ii33
Autor:
Emiliano Calvo, Rafael Santana-Davila, Jin Jin, Hendrik-Tobias Arkenau, Gu Mi, Roy S. Herbst, David Ferry, Ian Chau, Johanna C. Bendell, Charles S. Fuchs, Jessicca Rege
Publikováno v:
Journal of Clinical Oncology. 35:4046-4046
4046 Background: Angiogenesis and immunosuppression are hallmarks of tumor growth. This is the first study to combine R (anti-VEGFR2) with P (anti-PD-1) to simultaneously target both processes in the tumor microenvironment. Methods: Ongoing, multi-co
Autor:
Daniel P. Petrylak, David Ferry, Jose Luis Perez-Gracia, Roy S. Herbst, J. Yang, Jessicca Rege, Matthew G Krebs, Gu Mi, Rafael Santana-Davila, Hendrik-Tobias Arkenau
Publikováno v:
Journal of Clinical Oncology. 35:349-349
349 Background: Hallmarks of tumor growth include immunosuppression and angiogenesis. This is the first study to combine R (anti-VEGFR2) with P (anti-PD-1) to simultaneously target both processes in the urothelial tumor microenvironment. Methods: Thi
Autor:
Emiliano Calvo, Jordi Rodon Ahnert, David Ferry, Nicolas Penel, Roy S. Herbst, Jessicca Rege, Ian Chau, Gu Mi, Johanna C. Bendell, J. Yang, Charles S. Fuchs, Hendrik-Tobias Arkenau, Rafael Santana-Davila
Publikováno v:
Journal of Clinical Oncology. 35:102-102
102 Background: Angiogenesis and immunosuppression are hallmarks of tumor growth. This is the first study to combine R (anti-VEGFR2) with P (anti-PD-1) to simultaneously target both processes in the tumor microenvironment. Methods: This ongoing, mult
Autor:
Jessicca Rege, Emiliano Calvo, Jose Luis Perez-Gracia, David Ferry, Philippe A. Cassier, Nicolas Isambert, Johanna C. Bendell, J. Yang, Roy S. Herbst, Juan Martin-Liberal, Luis Paz-Ares, Gu Mi
Publikováno v:
Annals of Oncology. 27:vi574